Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration

Archives of Ophthalmology

Volumn 130, Issue 6, 2012, Pages 794-795

  Campbell, John P ^a   Bressler, Susan B ^a   Bressler, Neil M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN ANTIBODY;

AGED; ARTICLE; BLINDNESS; COHORT ANALYSIS; FOLLOW UP; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; ANGIOGENESIS INHIBITORS; BLINDNESS; FEMALE; HUMANS; LASER COAGULATION; MALE; PHOTOCHEMOTHERAPY; PREVALENCE; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION, LOW; VISUAL ACUITY; VISUALLY IMPAIRED PERSONS; WET MACULAR DEGENERATION;

EID: 84862180706     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.2480     Document Type: Article

References (3)

1. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of theANCHORstudy. Ophthalmology. 2009;116(1):57-65, e5.
2. Rosenfeld PJ, Brown DM, Heier JS, et al MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl JMed. 2006; 355(14):1419-1431. (Pubitemid 44511557)
3. Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011;129(6):709-717.